Literature DB >> 24929842

Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence.

Alexander J Gill1, Dennis L Kolson.   

Abstract

HIV-associated neurocognitive disorders (HAND) is a group of syndromes of varying degrees of cognitive impairment affecting up to 50 % of HIV-infected individuals. The neuropathogenesis of HAND is thought to be driven by HIV invasion and productive replication within brain perivascular macrophages and endogenous microglia, and to some degree by restricted infection of astrocytes. The persistence of HAND in individuals experiencing suppression of systemic HIV viral load with antiretroviral therapy (ART) is incompletely explained, and suggested factors include chronic inflammation, persistent HIV replication in brain macrophages, effects of aging on brain vulnerability, and co-morbid conditions including hepatitis C (HCV) co-infection, substance abuse, and CNS toxicity of ART, among other factors. This review discusses several of these conditions: chronic inflammation, co-infection with HCV, drugs of abuse, aging, and antiretroviral drug effects. Effectively managing these co-morbid conditions in individuals with and without HAND is critical for improving neurocognitive outcomes and decreasing HIV-associated morbidity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24929842      PMCID: PMC4188391          DOI: 10.1007/s11904-014-0210-3

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  100 in total

1.  Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs.

Authors:  S Czub; E Koutsilieri; S Sopper; M Czub; C Stahl-Hennig; J G Müller; V Pedersen; W Gsell; J L Heeney; M Gerlach; G Gosztonyi; P Riederer; V ter Meulen
Journal:  Acta Neuropathol       Date:  2001-02       Impact factor: 17.088

Review 2.  Neurocognitive dysfunction in the highly active antiretroviral therapy era.

Authors:  Nomvuyo Z Mothobi; Bruce J Brew
Journal:  Curr Opin Infect Dis       Date:  2012-02       Impact factor: 4.915

3.  Activation of brain macrophages/microglia cells in hepatitis C infection.

Authors:  Jeffrey Wilkinson; Marek Radkowski; Jennifer M Eschbacher; Tomasz Laskus
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

Review 4.  Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Authors:  Anupam Banerjee; Marianne Strazza; Brian Wigdahl; Vanessa Pirrone; Olimpia Meucci; Michael R Nonnemacher
Journal:  J Neurovirol       Date:  2011-07-07       Impact factor: 2.643

Review 5.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

6.  CD14(high)CD16(+) rather than CD14(low)CD16(+) monocytes correlate with disease progression in chronic HIV-infected patients.

Authors:  Junyan Han; Beibei Wang; Ning Han; Yan Zhao; Chuan Song; Xin Feng; Yu Mao; Fujie Zhang; Hongxin Zhao; Hui Zeng
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

7.  Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders.

Authors:  Claude Ann Mellins; Jennifer F Havens; Cheryl McDonnell; Carolyn Lichtenstein; Karina Uldall; Margaret Chesney; E Karina Santamaria; James Bell
Journal:  AIDS Care       Date:  2009-02

8.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

9.  The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Authors:  Perrine Roux; M Patrizia Carrieri; Virgine Villes; Pierre Dellamonica; Isabelle Poizot-Martin; Isabelle Ravaux; Bruno Spire
Journal:  Addiction       Date:  2008-09-04       Impact factor: 6.526

10.  Cocaine-mediated alteration in tight junction protein expression and modulation of CCL2/CCR2 axis across the blood-brain barrier: implications for HIV-dementia.

Authors:  Navneet K Dhillon; Fuwang Peng; Sirosh Bokhari; Shannon Callen; Sun-Hye Shin; Xuhui Zhu; Kee-Jun Kim; Shilpa J Buch
Journal:  J Neuroimmune Pharmacol       Date:  2007-11-29       Impact factor: 4.147

View more
  32 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.

Authors:  Robert C Kalayjian; Kevin R Robertson; Jeffrey M Albert; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo
Journal:  J Acquir Immune Defic Syndr       Date:  2019-06-01       Impact factor: 3.731

Review 3.  HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.

Authors:  Bianca Cotto; Kalimuthusamy Natarajanseenivasan; Dianne Langford
Journal:  Prog Neurobiol       Date:  2019-05-18       Impact factor: 11.685

4.  Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice.

Authors:  Aditya N Bade; Santhi Gorantla; Prasanta K Dash; Edward Makarov; Balasrinivasa R Sajja; Larisa Y Poluektova; Jiangtao Luo; Howard E Gendelman; Michael D Boska; Yutong Liu
Journal:  Mol Neurobiol       Date:  2015-06-11       Impact factor: 5.590

5.  Investigating the role of ankyrin-rich membrane spanning protein in human immunodeficiency virus type-1 Tat-induced microglia activation.

Authors:  Vir B Singh; Alicia K Wooten; Joseph W Jackson; Sanjay B Maggirwar; Michelle Kiebala
Journal:  J Neurovirol       Date:  2015-01-31       Impact factor: 2.643

Review 6.  Investigational protease inhibitors as antiretroviral therapies.

Authors:  Narasimha M Midde; Benjamin J Patters; Pss Rao; Theodore J Cory; Santosh Kumar
Journal:  Expert Opin Investig Drugs       Date:  2016-08-02       Impact factor: 6.206

7.  Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.

Authors:  Theodore R Miller; Jeffrey J Weiss; Norbert Bräu; Douglas T Dieterich; Alicia Stivala; Monica Rivera-Mindt
Journal:  J Neurovirol       Date:  2016-11-28       Impact factor: 2.643

8.  Aging alters voltage-gated calcium channels in prefrontal cortex pyramidal neurons in the HIV brain.

Authors:  Christina E Khodr; Lihua Chen; Lena Al-Harthi; Xiu-Ti Hu
Journal:  J Neurovirol       Date:  2017-10-31       Impact factor: 2.643

9.  HIV gp120-induced neuroinflammation potentiates NMDA receptors to overcome basal suppression of inhibitory synapses by p38 MAPK.

Authors:  Xinwen Zhang; Matthew V Green; Stanley A Thayer
Journal:  J Neurochem       Date:  2019-01-18       Impact factor: 5.372

10.  HIV gp120 upregulates tonic inhibition through α5-containing GABAARs.

Authors:  Matthew V Green; Stanley A Thayer
Journal:  Neuropharmacology       Date:  2019-02-20       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.